This article compares those pathways using FDA and manufacturer disclosures and platform terms as of December 26, 2025
Tirzepatide 15 mg vs cagrilintide/semaglutide (CagriSema): The combination of cagrilintide and semaglutide adds amylin receptor agonism to GLP-1 activation
The side effects are real, but the evidence consistently shows they are manageable, temporary for most people, and far outweighed by the benefits for patients who use the medication correctly and with proper clinical support
Here are some key findings: Within six months of starting GLP-1 therapy, the rate of hypotensive events increased from 8.7% to 10.2% The increased risk remained significant at 12 months, with hypotensive events rising from 13.6% to 14.3% Adults age 65 and older accounted for 53% of hypotensive events despite representing 37% of the study population Patients with Type 2 diabetes made up 75% of those experiencing hypotensive episodes but only 63% of the overall cohort In secondary analyses, the scientists found that weight loss alone did not explain the increased risk, suggesting other mechanisms of action may be at play Northwestern Now posed five questions to the study senior author Dr
Gastrointestinal adverse effects represent the most commonly observed side effects of Semaglutide / Cyanocobalamin Injection, occurring in a substantial proportion of patients, particularly during the initial weeks of treatment or following dose escalations
